PANWARFIN
LOE ApproachingNDAORALTABLET
Approved
Aug 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PANWARFIN is an oral anticoagulant tablet approved in 1972 by Abbott operating as a small-molecule NDA. The generic name and specific indications are not publicly detailed in available records, but the product represents a legacy anticoagulation therapy. As a 50+ year old oral tablet, it competes in a mature therapeutic class with significant generic and branded alternatives.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), indicating contracting team size and defensive commercial strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PANWARFIN offers limited growth opportunity and is best suited for professionals seeking experience in mature product management, defensive marketing, or managed care navigation in a declining market. Career advancement will require transition to growth-stage products or portfolio diversification.
Brand ManagerField Sales Representative
Worked on PANWARFIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.